Product Description
a novel microsomal prostaglandin e synthase 1 inhibitor (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26351780/)
Mechanisms of Action: MPGES Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Acute Pain
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
I6H-MC-MCBB | P1 |
Completed |
Healthy Volunteers |
2013-12-01 |
|
I6H-MC-MCBC | P2 |
Completed |
Acute Pain |
2013-10-01 |
|
I6H-MC-MCBD | P1 |
Terminated |
Healthy Volunteers |
2013-10-01 |
|
I6H-MC-MCBA | P1 |
Completed |
Healthy Volunteers |
2012-09-01 |